BRAF and melanoma: This hypothesis is supported by a clinical phase III trial that reported a significantly decreased recurrence of completely resected, stage III melanoma with BRAF-V600E or -V600K mutations treated with a combination of BRAF and MEK inhibitors after surgery (63).